Newsfeeds - Spark Newswire

1 minute read

Verve Therapeutics Reported New Preclinical Data In Non-human Primates Demonstrating Potent, Durable, And Well-tolerated Editing Of The ANGPTL3 Gene Following The Administration Of VERVE-201

Today, 3:20 PM

VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH including the requirement for multiple oral, injectable, and intravenous infusions in each patient, often administered over

VERV

1 minute read

Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia

By Charles Gross

Today, 3:20 PM

Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).

VERV

1 minute read

Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics

By Vandana Singh

Today, 3:20 PM

Cantor Fitzgerald initiated coverage on Verve Therapeutics Inc (NASDAQ:VERV) with a Neutral rating and a price target of $21. The analyst says…

VERV

2 minute read

Cathie Wood Gets Elon Musk’s Attention Over Gene-Editing Therapy Potential: ‘Investors Chased The Dream Then. Now, They’re Running Away’

By Bhavik Nair

Today, 3:20 PM

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

ARKG

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 3:20 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

1 minute read

Analyst Beefs Up Beam Therapeutics Price Target, Says ‘Reward Is Now Skewed To Upside’

By Vandana Singh

Today, 3:20 PM

BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ:BEAM) from Market Perform to Outperform and raised the price target from $61 to…

BEAM

3 minute read

Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 3:20 PM

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

AGYS

2 minute read

Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health

By Bhavik Nair

Today, 3:20 PM

Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based on Tuesday’s closing price.

ARKG